Search Within

Elisa De Stanchina

  1. "Benjamin Lok"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (3)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (7)
  2. Center for Molecular Imaging and Biotechnology (CMIB) (7)
  3. Department of Medicine (7)
  4. GSK Faculty (7)
  5. Solid Tumor Oncology Division (7)
  6. Thoracic Oncology (7)

More Groups

People
  1. Benjamin Lok (7)
  2. Charles Rudin (7)
  3. John Poirier (7)
  4. Eric Gardner (3)
  5. James Laird (3)
  6. Ai Ni (2)

More People

Years
  1. 2019 (1)
  2. 2018 (2)
  3. 2017 (3)
  4. 2016 (1)
Publications
  1. Clinical Cancer Research (2)
  2. International Journal of Radiation Oncology, Biology, Physics (2)
  3. Journal of Thoracic Oncology (2)
  4. Cancer Cell (1)
Publishers
  1. Elsevier Inc. (4)
  2. American Association for Cancer Research (2)
  3. Cell Press (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Positron-emission tomographic imaging of a fluorine 18-radiolabeled Poly(ADP-ribose) polymerase 1 inhibitor monitors the therapeutic efficacy of talazoparib in SCLC patient-derived xenografts
    Journal Article

    Laird, J.; Lok, B. H.; Carney, B.; Kossatz, S.; de Stanchina, E.; Reiner, T.; Poirier, J. T.; Rudin, C. M.
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • PARP inhibitor radiosensitization of small cell lung cancer differs by PARP trapping potency
    Meeting Abstract

    Lok, B.; Laird, J.; Ma, J.; De Stanchina, E.; Poirier, J.; Rudin, C.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Talazoparib is a potent radiosensitizer in small cell lung cancer cell lines and xenografts
    Journal Article

    Laird, J. H.; Lok, B. H.; Ma, J.; Bell, A.; de Stanchina, E.; Poirier, J. T.; Rudin, C. M.
    Clinical Cancer Research (2018)

    Fulltext@MSK | Save
  • [(18)F]PARPi PET as a marker of intratumoral talazoparib level in small cell lung cancer
    Meeting Abstract

    Laird, J. H.; Lok, B. H.; Carney, B.; Kossatz, S.; Ma, J.; Bell, A.; Shah, N.; Sadique, A.; De Stanchina, E.; Reiner, T.; more...
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save
  • PARP Inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer
    Journal Article

    Lok, B. H.; Gardner, E. E.; Schneeberger, V. E.; Ni, A.; Desmeules, P.; Rekhtman, N.; De Stanchina, E.; Teicher, B. A.; Riaz, N.; Powell, S. N.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis
    Journal Article

    Gardner, E. E.; Lok, B. H.; Schneeberger, V. E.; Desmeules, P.; Miles, L. A.; Arnold, P. K.; Ni, A.; Khodos, I.; de Stanchina, E.; Nguyen, T.; more...
    Cancer Cell (2017)

    Fulltext@MSK | Save
  • SLFN11 is necessary for single agent sensitivity to talazoparib, a potent PARP inhibitor, but not for radiosensitization in small cell lung cancer (SCLC) cell lines and patient-derived xenografts (PDX)
    Meeting Abstract

    Lok, B. H.; Feng, Y.; Gardner, E. E.; Yu, G. K.; Ru, Y. K.; Riaz, N.; deStanchina, E.; Powell, S. N.; Shen, Y. J.; Poirier, J. T.; more...
    International Journal of Radiation Oncology, Biology, Physics (2016)

    Fulltext@MSK | Save